ICN Biomedicals launches cardiovascular risk test:
This article was originally published in Clinica
ICN Biomedicals, a subsidiary of ISN Pharmaceuticals, has begun selling a high-sensitivity test for the detection of chronic inflammation associated with coronary heart disease. The product measures C-Reactive protein - chronic low levels of this market represent a potential higher risk of cardiovascular disease, ICN says. The Costa Mesa, California company says that nearly half of the 1.3 million people suffering heart attacks annually in the US have no symptoms that could have been detected with conventional cholesterol or lipid marker tests.